Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?
Year: 2010
Type: review
Abstract: With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.
Source: Neuro-Oncology
Authors: A. B. Heimberger, J. H. Sampson
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Accelerate Brain Cancer Cure, Rose Foundation for Communities and the Environment, Pfizer, Neurosurgery Research and Education Foundation, Congress of Neurological Surgeons, Golfers Against Cancer, Celldex Therapeutics, Dr. Marnie Rose Foundation, National Institutes of Health, University of Texas MD Anderson Cancer Center, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Neurological Disorders and Stroke
Awards: Intracerebral Infusion of Radiolabeled Specific Antibody, G1676890253, Dendritic Cell Immunotherapy of Malignant Gliomas, RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells, G1897835015, NINDS Research Education Programs for Residents and Fellows in Neurosurgery, G2757794573, G312017549, SRC on Primary Tumors of the CNS, G5573147988, Effect on IL-2R Antibody on Regulatory T-cells in Patients with Malignant Gliomas, G6121528890, G6284015831, SPORE in Brain Cancer, Inhibition of STAT-3 to stimulate immune function for GBM, G8216250184, SPORE in Brain Cancer
OpenAlex ID: W2169705294